SLEDAI-2K for 1 year as gold standard. After categorizing moderate to severe ≥ 3 of SLEDAI-2K, sensitivity, specificity, positive predictive values (PPV), and negative predictive values for the algorithms to detect patients with moderate to severe SLE were estimated.

**Results**
We included 151 patients with SLE. Their mean age was 34.5 ± 8.8, and 94.7% were female, presenting initial SLEDAI-2K score of 3.8 ± 3.2. For classifying moderate to severe SLE, the PPV of claims-based algorithm ranged from 75.86 to 77.19%. The algorithms (4) and (5) improved PPV up to 77.19%. However, the algorithms modifying glucocorticoid dose to differentiate between moderate and severe SLE or considering any prescriptions of intravenous glucocorticoid did not increase the PPV.

**Conclusions**
The algorithm using diagnostic codes for comorbidities and medications demonstrated PPV of 77.19% to detect moderate to severe SLE. It may be a useful for classifying SLE severity in Korean claims database studies.

**LP-074**
**COST-OF-ILLNESS CHANGES BEFORE AND AFTER DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS: A NATIONALWIDE POPULATION-BASED COHORT STUDY IN KOREA**

1Hyungyoung Kim, 1Soo-Kyung Cho, 1Jung-Yong Han, 2Yena Jeon, 3Sun-Young Jung, 4Im Jiin Jang, 5Yoon-Kyoung Sung. 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Republic of Korea; 2Department of Statistics, Kyungpook National University, Republic of Korea; 3College of Pharmacy, Chung-Ang University, Republic of Korea; 4Department of Information Statistics, Andong National University, Republic of Korea

**Background**
Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder with various ranges of organ damages, so that patients with SLE might face to considerable medical costs in their early disease courses. We aimed to estimate the progression of direct healthcare costs before and after diagnosis of SLE and to compare healthcare costs by disease severity in Korean patients with SLE.

**Methods**
Incident patients with SLE were identified between 2008 and 2018 using the Korean National Health Insurance databases. Annual direct healthcare costs for five years before and after the diagnosis of SLE were estimated and we compared them with those of age-, sex-, and calendar months-matched controls (1:4). Direct healthcare costs of patients with SLE were compared by disease severity using inverse probability-weighted regression analysis.

**Results**
A total of 11,173 incident SLE patients and 45,500 subjects without SLE were identified. Annual direct healthcare costs per person in SLE group was increasing one year before SLE diagnosis, and reached the highest at the first year of SLE diagnosis, resulting 7.7-fold greater than comparators ($5,694 vs. $736 a year, respectively). Among patients with SLE, having severe SLE resulted in 4.39 times (95% Confidence Interval [CI] 4.123–4.673) higher cost over a period of 1 year. Older age (aged 70–79, 1.455 times, 95% CI 1.304–1.623), having comorbidities such as lupus nephritis (1.89 times, 95% CI 1.801–1.983), avascular necrosis (5.482 times, 95% CI 3.977–7.668), chronic kidney diseases (1.783 times, 95% CI 1.601–1.985), and interstitial lung diseases (1.542 times, 95% CI 1.346–1.765) were associated with higher annual direct healthcare costs of the first year.

**Conclusions**
Patients with SLE incurred significantly high direct healthcare costs compared to subjects without SLE, especially during the first year after diagnosis. Disease severity as well as comorbidities were associated with increased costs of illness in patients with SLE.

**LP-073**
**IDENTIFICATION OF SYSTEMIC LUPUS ERYTHEMATOSUS CLASSIFICATION CRITERIA ATTRIBUTES IN A REGIONAL MEDICAL RECORD DATA NETWORK**

1Noah Forrest, 1Kathryn Jackson, 2Jennifer Pacheco, 1Vesna Mitrovic, 1Alona Fumanchuk, 1Abel Kho, 2Rosalind Ramsey-goldman, 2Theresa Walunas. 1Center for Health Information Partnerships, Northwestern University, USA; 2Center for Genetic Medicine, Northwestern University, USA

**Description**
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by a multi-systemic presentation.1 Patients with SLE will often see multiple providers operating within different healthcare networks, meaning that pieces of important data related to patients’ disease course may be spread across disparate electronic health records2 (EHR). One method for integrating EHR data from multiple sites leverages clinical data research networks (CDRNs), such as the Chicago Area Patient Centered Outcomes Research Network (CAPriCORN),3 which includes data from 11 healthcare sites.

**Conclusions**
These results highlight the importance of linking information across multiple healthcare sites in the context of complex diseases such as SLE, as disease-specific information can be gained through data aggregation. Systems such as CAPriCORN may have important applications in improving recruitment for clinical trials, clinical decision-making for rheumatologists, and population-level surveillance of SLE.

**References**

10.1136/lupus-2023-KCR.184

**LP-078**
**CHARACTERIZATION OF A COHORT OF PATIENTS WITH A DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS FOLLOWED-UP IN THE CITY OF CALI, COLOMBIA**

1Diana Fernández, 1Daniel Fernández, 1John Jaramillo, 1Alfredo Vargas, 1Carlos Toro. 1Rheumatology, Organización Sanitas Internacional, Bogotá, Colombia; 2Rheumatology, Hospital San Ignacio – Pontificia Universidad Javeriana, Bogotá, Colombia; 3Rheumatology, Centro de Referencia en Osteoporosis, Reumatología y Dermatología, Cali, Colombia; 4Rheumatology, Hospital Italiano de Buenos Aires, Argentina; 5Rheumatology, Centro de Referencia en Osteoporosis, Reumatología y Dermatología, Cali, Colombia

**Background**
Diseases such as systemic lupus erythematosus (SLE), juvenile idiopathic arthritis (JIA), and rheumatoid arthritis (RA) can have a significant impact on disability and productivity, both economic and emotional. Aiming to improve patients’ quality of life, it is crucial to monitor disease progression over time. This study aimed to characterize a cohort with systemic lupus erythematosus (SLE) followed-up in the city of Cali, Colombia, from 2005 to 2020.

**Methods**
A cohort of patients with SLE followed-up in the city of Cali, Colombia, from 2005 to 2020 was characterized. The study was conducted at the University of the Andes, Cali, Colombia, and the study population consisted of patients with a confirmed diagnosis of SLE by a rheumatologist. The data were collected through medical records and clinic notes. The study outcomes included disease activity measures, comorbidities, and patient-reported outcomes.

**Results**
A total of 150 patients with SLE were included in the study. The median age at diagnosis was 35 years (range: 1–80 years). The median disease duration was 10 years (range: 0–30 years). The most common comorbidities were hypertension (40%), diabetes mellitus (20%), and obesity (15%). The median SLE Disease Activity Index (SLEDAI) score was 4 (range: 0–24). The median Health Assessment Questionnaire (HAQ) score was 0.5 (range: 0–2.0).

**Conclusions**
This study provides a detailed characterization of a cohort of patients with SLE followed-up in the city of Cali, Colombia, from 2005 to 2020. The study outcomes highlight the impact of comorbidities and disease activity on patients’ quality of life. This information can be used to tailor treatment plans and monitor disease progression over time.